Wang, Sean K.
Korot, Edward
Zaidi, Moosa
Ji, Marco H.
Al-Moujahed, Ahmad
Callaway, Natalia F.
Kumm, Jochen
Moshfeghi, Darius M.
Article History
Received: 25 October 2021
Accepted: 9 March 2022
First Online: 18 March 2022
Competing interests
: S.K.W., None; E.K., Genentech (C), RetiHealth Inc (C,E);, M.Z., None; M.H.J., None; A.A., None; N.F.C, Genentech (E); J.K., Pr3vent INC (F,CEO); D.M.M, 1-800Contacts (BOD,E), Akceso Advisors AG (C), Akebia (SAB), Alcon (C), Aldeyra Therapeutics (PI), Alexion (C), Allegro (SAB), Apellis (PI), Bayer Pharma AG (SC,C), CMEOutfitters.com (C), Congruence Medical Solutions (C), dSentz, Inc. (F,E,BOD), Grand Legend Technology, LTD (E), Iconic Therapeutics (SC), Irenix (SAB), Linc (F,E,BOD), M3 Global Research (C), Northwell Health (C), Novartis Pharmaceuticals (DMC, C), Ocular Surgery News (C), Pr3vent INC (F,E,BOD), Praxis UNS, Inc. (C), Prime Medical Education (C), Promisight, Inc (F,E,BOD), Pykus (E,SAB), Regeneron (SC,PI), Retina Technologies LLC (SAB,C,E), Retina Today/Pentavision (C), Shapiro Law Group (C), SLACK, Inc (C), Versl, Inc. (F,E), Vindico (C), Visunex (E,SAB).